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INTRODUCTION
Angiotensin-converting enzyme 2 (ACE2) is an aminopeptidase that converts Angiotensin (Ang)
II into Ang (1-7). Coronavirus uses ACE2 as a cellular receptor to invade target cells. In particular,
the spike protein of SARS-CoV-2 (the beta-coronavirus responsible for Covid-19) is processed
by transmembrane protease-serine 2 (TMPRSS2) and favors the binding of the spike protein to
ACE2 (1–3).
It is well-known that Ang II, acting on AT1 receptors, exerts powerful vasoconstrictor,
pro-fibrotic, and pro-inflammatory effects. In contrast, Ang (1-7), acting onMas receptors (MasR),
is a potent vasodilator, anti-apoptotic, and anti-proliferative agent (Figure 1). Therefore, ACE2 is
a negative regulator of classical ACE in the renin-angiotensin system (RAS). The two enzymes
are involved in maintaining the homeostasis of RAS and in regulating blood pressure as well as
the fluid and salt balance. The human ACE2 gene is located on chromosome Xp22. Moreover, the
ACE/ACE2 activity ratio in females is lower than that in the male serum. This different ratio may be
partially attributed to the two X chromosomes and to estrogens effect on ACE2 activity (4). In both
sexes, ACE2 is largely expressed in lungs, liver, intestine, brain, heart, and kidneys, and also in testes.
In almost all the pathological conditions, especially those of the cardiovascular system, there is an
increase in the ACE/ACE2 ratio within the organs and systems (5–9). This ACE/ACE2 imbalance
is very often due to a downregulation of ACE2 levels, and this ratio alteration is accompanied
by disturbance in RAS homeostasis. For instance, it has been found that the ACE/ACE2 ratio is
high in the glomeruli in the high-salt diet animals, and it is accompanied by renal dysfunction and
oxidative stress (5). Also, in the heart, a high-glucose diet upregulated ACE and downregulated
ACE2, leading to the augmentation of ACE/ACE2 ratio (6). Moreover, downregulation of ACE2
has been described in pulmonary arterial hypertension and cigarette smoker patients (7). The
ACE/ACE2 ratio increase was also correlated with the systolic blood pressure, the serum creatine
level, the fasting blood glucose level, and the proteinuria in humans (8). ACE2 is reduced, and the
ACE/ACE2 ratio increased also in Alzheimer’s disease in association with increasing amyloid-β and
tau pathology. (9). Notably, SARS-CoV-2, which binds with ACE2 to enter the targeted cells, also
leads to downregulation of ACE2. All in all, it seems that when ACE2 levels or activity are low and
the ACE/ACE2 ratio increases we are in trouble (Figure 1) and may be more at risk of having a
worse outcome in Covid-19 infection.
COVID-19 AND COMORBIDITIES
The Italian ISS (https://www.epicentro.iss.it/coronavirus/sars-cov-2-decessi-italia, accessed on
April 26th 2020) reports that among 23,188 SARS-CoV-2 patients dying in Italy, 3.6% patients
presented with no comorbidities, 14.4% with a single comorbidity, 21.1% with two, and 60.9% with
three or more comorbidities. Among these comorbidities, the most represented is hypertension
(69.1%), followed by ischemic heart disease (27.5%), chronic renal failure (21.1%), atrial fibrillation
(22%), pulmonary diseases (17.1%), heart failure (16.1%), and some other comorbidities with<15%
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FIGURE 1 | A higher ACE/ACE2 ratio may increase the risk of worse outcomes in Covid-19 infection. ACEi, ACE inhibitors; ARB, AT1R blockers; ACE,
angiotensin-converting enzyme; MasR, Mas receptor; rACE2, recombinant ACE2; ATR1, angiotensin receptor 1.
incidence. Of note is that all these pathologies are characterized
by themselves by a downregulation of ACE2 and a high
ACE/ACE2 ratio (10–14). The majority of deceased patients were
aged (over 60) and obese (in the Italian report, obesity is present
in 12.2% of deceased patients). In addition, these two conditions
are characterized by an increasing ACE/ACE2 ratio (15, 16).
Therefore, we wonder whether the invasion by SARS-CoV-2
and the downregulation of ACE2 are jointly responsible for a
high incidence of dramatic acute respiratory distress syndrome
(ARDS), cardiovascular complications, and high lethality of
Covid-19. Is it worthwhile to try to re-establish an appropriate
ACE/ACE2 ratio?
IF YOU CANNOT BREATHE, NOTHING
ELSE MATTERS
It has been reported that SARS-CoV-2 has an affinity for ACE2
that is 10 times higher in comparison to SARS-CoV’s affinity for
this enzyme (2). Is ACE2 like a Trojan horse (1)? Is it a gift of
nature that also allows the enemy to enter into cells? Should we
therefore say “timeo Danaos et dona ferentes”? We believe ACE2
is not an enemy. We believe it is almost an innocent witness to
the crime, and we will present here some clues to exculpate it. In
our opinion, ACE2 is the key for the virus to enter the organism,
but it is not responsible for the injury determined by the virus.
Of course, organs that express a high level of ACE2 are
the targets of SARS-CoV-2 infection. This virus diffuses and is
transmitted through human respiratory droplets. Therefore, the
lung is the principal and initial target organ of SARS-CoV-2
infection (3). The subsequent pathogenic mechanisms are not
strictly correlated with neither the number/expression of ACE2
and its activity nor with the viremia. For instance, a correlation
between viremia and ARDS in patients with severe Covid-19 has
not been observed (17). Moreover, estrogen shifts the system
toward the ACE2/Ang 1-7 formation and ACE2 activity is higher
in female than that in the male serum (18); however, the worst
and most lethal Covid-19 infections occur predominantly in
males [the Italian ISS (https://www.epicentro.iss.it/coronavirus/
sars-cov-2-decessi-italia, accessed on April 26th 2020) reports
that among 23,188 SARS-CoV-2 patients dying in Italy,
women are 8,500 (36.7%)]. We believe that the subsequent
inflammation and cytokine storm is responsible for the primum
movens for Covid-19 worsening rather than viremia. For
instance, viroporins-induced NLRP3/inflammasome activation
and excessive production of IL-1βmay be important pathological
mechanisms (19). After the virus enters the cells, ACE2 is
likely to decrease its activity, thus favoring an increase of the
ACE/ACE2 balance toward the prevalence of ACE arm in the
RAS. First of all, the prevalence of ACE arm determines a direct
increase of ROS production, vasoconstriction, and inflammation.
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Indeed, Ang II action on its AT1 receptors promotes NAD(P)H
oxidase upregulation, oxidative stress, and cytokine production
(20). Cytokine storm, ROS, and inflammation lead to vascular
permeability, diffuse alveolar damage, pulmonary edema, and,
eventually, to ARDS (21, 22). Which cells in the lungs mediate
this inflammatory response? It is likely that, among other cells,
macrophages may play a pivotal role. Indeed, macrophages
express ACE2 receptors (23), and three different macrophages
populations have been described by Tan and Krasnow (24) within
the respiratory tract. These three populations may respond
differently to virus infection, and the different representation of
these macrophages may explain the range of clinical scenarios
from asymptomatic, to paucisymptomatic, and to dramatic
pneumonia. This is a hypothesis that need to be ascertained.
Nevertheless, when the cytokine storm starts and edema/ARDS
ensue, hypoxia occurs, which may exacerbate vasoconstriction,
through the typical hypoxia-induced vasoconstriction in the
pulmonary vessels [for more details on cytokine storm the reader
is redirected to (19, 25)]. For some organs, such as the brain and
heart, hypoxia represents an intolerable condition that may lead
to lethal outcomes. Together a marked increase in macrophage
infiltration, hypoxia can mediate the myocardial damage that
accompanies the Covid-19 infection. In the heart, multiple
different macrophage subtypes have recently been identified
(26), and they can mediate the infection-induced injury. From
autopsies, it appears that only a third of patients who died for
cardiovascular complications, among Covid-19 patients, have
evidence of coronaviruses inside the myocardium (27). This is
another sign that it is not important how much virus enters but
how the organism reacts to the virus.
Chronic hypoxia-driven vasoconstriction contributes
significantly to pulmonary hypertension and several pulmonary
hypertension-related diseases, including edema, right heart
failure, and myocardial ischemic events (28). Paradoxically,
hypoxia may exacerbate redox stress through at least two
mechanisms: hypoxia-induced hyperventilation and subsequent
alkalosis and dysregulation of iron metabolism (29–32).
Pulmonary edema hypoxia is not easy to treat. Indeed, oxygen
therapy remains the major life-saving concern in intensive
care unit (ICU). In ICU-patients, excess oxygen delivery may
cause considerable harm in which redox stress plays a pivotal
role (33–35). Therefore, additional therapies that limit redox
stress and inflammation are needed, including those aimed at
improving the ACE/ACE2 ratio.
APPROACHES TO IMPROVE ACE/ACE2
RATIO
All the above data support the idea that an imbalance in
the ACE/ACE2 ratio may be a predisposing cause to the
worsening of the Covid-19. It has also been suggested that
the increased concentration of ACE2 receptors in in the lungs
of children may have a protective effect on severe clinical
manifestations due to SARS-CoV-2 invasion (36). Also, these
data support a negative correlation between ACE2 expression
and Covid-19 severe outcomes. Perhaps, therapies improving
this ratio may be useful in infected patients (37–40). The RAS
is quite complex, and several pharmacological approaches are
under evaluation to benefit from ACE downregulation and
ACE2 upregulation in a variety of pathological conditions,
especially cardiovascular diseases. ACE inhibitors (ACEi) and
AT1R blockers (ARB) upregulate the expression of ACE2 (37–
40). Potential direct activators of ACE2 are diminazene aceturate,
resorcinolnaphthalein, and xanthenone (41). Since SARS-CoV-2
spreads via the bloodstream to infect other organs, recombinant
ACE2 (rhACE2) has been proposed as a therapeutic approach
in pneumonia and Covid-19 (42–44). The soluble rhACE2 may
be a promising approach to quench the virus when it is in the
bloodstream (43, 44). However, it must be tested with caution,
as soluble ACE2 is not always associated with beneficial effects
(45). For instance, soluble ACE2 has a high level in men suffering
from heart failure (45, 46). However, as said above, this is a
condition associated with Covid-19 worsening; and this therefore
suggests that soluble ACE2 may not be sufficient to protect
patients. Membrane-bound ACE2 has greater anti-inflammatory
effects (47).
A natural way to upregulate membrane bound ACE2 and
to lower the ACE/ACE2 ratio is to exercise. It has been
reported several times that physical training, and especially
aerobic training may decrease ACE/Ang II, and synergistic
upregulates ACE2/Ang (1-7) axis (48, 49). Although someone
has put forward the hypothesis that excessive exercise is a way
to increase Trojan horses (ACE2) for SARS-CoV-2 invasion, the
evidence for the beneficial effects attributable to regular exercise
are overwhelming.
DISCUSSION AND CONCLUSIONS
All in all, the majority of data are in favor of the idea that a
high ACE/ACE2 ratio may be detrimental for Covid-19 infection.
ACE/ACE2 ratio is increased in many pathologies (especially
dis-metabolisms and cardiovascular diseases) and conditions
(obesity and aging) that exacerbate Covid-19 symptomatology
and worsen outcomes. Moreover, ACE2 is upregulated and
the ACE/ACE2 ratio is lower in many subjects at low risk
for cardiovascular diseases, such as females, exercise-trained
individuals, and patients well-treated with ACE inhibitors. Since
most of the deceased Covid-19 patients had hypertension, further
consideration is needed for ACEi and ARBs. The use of these
drugs has been questioned, but the majority of authors are in
favor of the use of these drugs (37–42). We agree that if used
correctly they reduce the ACE / ACE2 ratio and should also be
recommended to Covid-19 patients.
Are these subjects with a higher ACE2 and lower ACE/ACE2
ratio also protected against Covid-19 exacerbation? ACE2
expression could influence the course of Covid-19 in different
ways: increased expression might promote viral entry, whereas
ACE2 increased expression may be beneficial due to ACE2 anti-
inflammatory and other beneficial effects (Figure 1) that could
prevent pulmonary edema, ARDS, hypoxia, and redox stress
development. It is likely that viral load is not strictly related to
disease severity, and so it is likely that ACE2 overexpression is
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not responsible for Covid-19 worsening but that there is, rather,
some other mechanism within the complex RAS or outside of
RAS (such as a different macrophages population or a different
immune response) that may play a role. Covid-19 is associated
with an exaggerated and dysregulated systemic inflammatory
response involving several inflammatory cells and leading to
overproduction of several cytokines. We recently discussed in
a Review article (25) the cells and the cytokines likely involved
in the exacerbation of Covid-19. We pointed out how cytokine
storms on cardiac and vascular endothelium may facilitate the
onset of coagulopathies, thereby increasing the probability for
organ ischemia and for multiple pulmonary and cardiovascular
complications. The virus downregulates ACE2, exacerbating the
pro-inflammatory milieu of high ACE/ACE2 ratio.
Membrane-bound ACE2 has an anti-inflammatory role, and
an imbalanced and high ACE/ACE2 ratio is not recommended
(Figure 1): it is better to have a low ACE/ACE2 ratio.
Whether increasing the ACE2/Ang (1-7) axis by pharmacological
intervention or by regular exercise may limit Covid-19 worsening
remains to be ascertained. Of course, these hypotheses deserve
to be studied and must be confirmed with ad hoc researches.
Nevertheless, currently there are no effective and definitively
approved drugs for the treatment of Covid-19. Therefore,
understanding themolecular and cellular mechanisms that favors
or exacerbates the Covid-19 in patients with altered ACE/ACE2
ratio and with comorbidities in general is urgent and necessary to
design some truly effective therapies. In the meantime, we await
a therapy or a vaccine; we can exercise, though we recommend
to do this at home or alone to limit the diffusion of this
terrible pandemic.
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